Keypoints:
• KEYNOTE-799: Exploring the combination of concurrent chemotherapy and radiation with the PD-1 inhibitor pembrolizumab for unresectable non-small cell lung cancer (NSCLC).
• LAURA: The impact of osimertinib in patients with EGFR mutations post-chemoradiation therapy.
• MARIPOSA: The promising results of amivantamab and lisertinib in the metastatic setting for EGFR-mutated NSCLC.
• KRYSTAL-7: Investigating the use of KRAS G12C inhibitors in frontline therapy.
In this episode of the Oncology Brothers podcast, Drs. Rahul & Rohit Gosain, along with the guest Dr. Joshua Sabari, a thoracic medical oncologist from NYU, dived into the key studies presented at the European Lung Cancer Conference (ELCC) 2025. Focus was on several practice-informing studies that are crucial for our community.
We started with the KEYNOTE-799 study, which explored the combination of concurrent chemotherapy and radiation with the PD-1 inhibitor pembrolizumab for patients with unresectable non-small cell lung cancer (NSCLC). Dr. Sabari shared insights on the impressive median overall survival rates observed, although he noted that the regimen is not yet ready for widespread clinical use until more randomized phase 3 data is available.
Next, we discussed the LAURA study, which highlighted the use of osimertinib in patients with EGFR mutations after concurrent chemo-radiation therapy. The findings reaffirmed osimertinib as the standard of care in this setting, emphasizing the importance of comprehensive genetic testing to avoid inappropriate immunotherapy.
We shifted gears, and delved into the metastatic space, particularly focusing on the MARIPOSA study, which evaluated the combination of amivantamab and lazertinib. Dr. Sabari discussed the significant improvement in overall survival and the management of associated side effects, which is critical for patient care.
Finally, we touched on the KRYSTAL-7 study, which investigated the use of KRAS G12C inhibitors in the frontline setting. While the data is promising, Dr. Sabari advised caution until more mature data is available.
Throughout the episode, we stressed the importance of genetic testing, the management of side effects, and the need for ongoing clinical trials to improve patient outcomes.
Listen Podcast on Your Favourite Platform
